A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

cardiac function as measured by changes in Left Ventricular Shortening Fraction (LVSF), Left Ventricular Ejection Fraction (LVEF) and Left Ventricular (LV) mass using echocardiogram (ECHO),

quality of life using quality-of-life surveys, and

functional status using Activities of Daily Living (ADL).

Condition or disease

Intervention/treatment

Phase

Friedreich's Ataxia

Drug: placeboDrug: deferiprone

Phase 1Phase 2

Detailed Description:

This will be a multi-centre, double-blind, randomized, placebo-controlled clinical trial. A total of 80 patients with Friedreich's ataxia will be enrolled. Eligible patients will receive deferiprone oral solution or placebo at a total daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day, divided into two-daily doses for 6 months.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

7 Years to 35 Years (Child, Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Diagnosis of FRDA, with confirmed mutation (excludes point mutation) in the frataxin (FXN) gene and GAA repeats ≥ 400 on the shorter allele.

Males or females aged 7 to 35 years.

No exposure to idebenone, coenzyme Q10, vitamin C, vitamin E or other antioxidants as a supplement or as a drug therapy for a period of at least one month prior to start of treatment and during the study.

Neurological testing: A FARS score >20 and <85 at Screening and Baseline.

Female subjects of childbearing potential must have a negative pregnancy test at Baseline.

If the subject is a heterosexual, sexually-active male, he confirms that he and/or his female partner will use an effective method of contraception for the length of the trial and for 30 days following completion of the study or early termination.

Signed and witnessed written informed consent/assent, obtained prior to the first study intervention, as well as the ability to adhere to study restrictions, appointments and evaluation schedule.

Unable to complete T25FW AND with score > 5 minutes in the 9HPT. (Subjects who can complete T25FW or with a score ≤ 5 minutes in the 9HPT will be allowed to enroll if the score has not doubled compared to screening).

Abnormal ALT, greater than 2.0 times the upper limit of normal on two consecutive assessments.

Serum creatinine outside the normal reference range.

History or evidence of neutropenia defined by an absolute neutrophil count (ANC) < 1.5 x 109/L or thrombocytopenia defined by a platelet count <150 x 109/L.

Refusal to participate in screening procedures or unable to participate in screening procedures or unable to comply with the requirements of the protocol.

Receiving any investigational drug products or having received any investigational product within 30 days prior to enrollment into this study.

Subjects who have previously taken deferiprone.

Subjects who, in the opinion of the Investigator, represent poor medical, psychological or psychiatric risks, and for whom participation in an investigational trial would be unwise.

Pregnant, breastfeeding or planning to become pregnant during the study period.

History of malignancy.

History of alcohol or drug abuse.

Investigators, site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

Hypersensitivity to the active substance (deferiprone) or any of the excipients in the oral solution.